Compare GPRE & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | FTRE |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 829.3M |
| IPO Year | 2004 | 2023 |
| Metric | GPRE | FTRE |
|---|---|---|
| Price | $15.98 | $9.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $11.31 | ★ $14.17 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,091,680,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.85 | $3.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $3.14 | $3.97 |
| 52 Week High | $17.94 | $18.67 |
| Indicator | GPRE | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 41.04 |
| Support Level | $9.25 | $8.80 |
| Resistance Level | $16.80 | $11.22 |
| Average True Range (ATR) | 0.97 | 0.65 |
| MACD | -0.20 | 0.11 |
| Stochastic Oscillator | 41.10 | 30.71 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.